33.41
전일 마감가:
$33.58
열려 있는:
$33.37
하루 거래량:
583.04K
Relative Volume:
1.00
시가총액:
$1.87B
수익:
$651.97M
순이익/손실:
$59.71M
주가수익비율:
31.24
EPS:
1.0696
순현금흐름:
$172.03M
1주 성능:
+0.54%
1개월 성능:
+7.22%
6개월 성능:
-14.66%
1년 성능:
+8.65%
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
Supernus Pharmaceuticals Inc
전화
301-838-2500
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
SUPN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SUPN
Supernus Pharmaceuticals Inc
|
33.41 | 1.88B | 651.97M | 59.71M | 172.03M | 1.0696 |
![]()
ZTS
Zoetis Inc
|
150.75 | 67.73B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.31 | 45.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.70 | 44.38B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.51 | 18.97B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
298.14 | 13.73B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-19 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
2024-09-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2023-01-03 | 재개 | Jefferies | Buy |
2021-12-01 | 재개 | Jefferies | Buy |
2021-04-13 | 업그레이드 | Jefferies | Hold → Buy |
2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2020-06-15 | 재개 | Jefferies | Hold |
2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold |
2019-11-07 | 다운그레이드 | Stifel | Buy → Hold |
2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
2018-11-12 | 재확인 | B. Riley FBR | Buy |
2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy |
2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy |
2017-12-04 | 업그레이드 | Janney | Neutral → Buy |
2017-11-08 | 업그레이드 | Stifel | Hold → Buy |
2017-10-19 | 개시 | FBR & Co. | Buy |
2017-09-19 | 다운그레이드 | Stifel | Buy → Hold |
2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
2017-07-14 | 개시 | Janney | Neutral |
2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
2016-02-08 | 업그레이드 | Jefferies | Hold → Buy |
2015-11-05 | 재확인 | Northland Capital | Outperform |
2015-10-28 | 개시 | Northland Capital | Outperform |
모두보기
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Supernus announces expiration of HSR waiting period for Sage Therapeutics - TipRanks
Supernus-Sage acquisition clears antitrust hurdle as HSR waiting period expires - Investing.com Australia
Supernus Pharmaceuticals Announces Expiration of - GlobeNewswire
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - Benzinga
Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan
Is Supernus Pharmaceuticals Inc. a growth stock or a value stockMaximize portfolio growth with strategic plans - jammulinksnews.com
How many analysts rate Supernus Pharmaceuticals Inc. as a “Buy”Free Risk Assessment Services - jammulinksnews.com
What is the dividend policy of Supernus Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - jammulinksnews.com
What are the technical indicators suggesting about Supernus Pharmaceuticals Inc.Unlock powerful market analysis and alerts - jammulinksnews.com
Why is Supernus Pharmaceuticals Inc. stock attracting strong analyst attentionAccess exclusive market insights for free - jammulinksnews.com
What are the latest earnings results for Supernus Pharmaceuticals Inc.Accelerated investment success - jammulinksnews.com
Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum? - 富途牛牛
What institutions are buying Supernus Pharmaceuticals Inc. stock nowBreakthrough stock performance - jammulinksnews.com
What drives Supernus Pharmaceuticals Inc. stock priceDouble or triple returns - PrintWeekIndia
What analysts say about Supernus Pharmaceuticals Inc. stockRapid wealth creation - Autocar Professional
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - FinancialContent
What makes Supernus Pharmaceuticals Inc. stock attractive to long term investorsBreakout portfolio performance - jammulinksnews.com
Is Supernus Pharmaceuticals Inc. a good long term investmentExtraordinary performance - Autocar Professional
Supernus Pharmaceuticals Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price - simplywall.st
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen - MarketBeat
Published on: 2025-07-23 12:28:32 - Autocar Professional
Supernus Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 5 - Nasdaq
Supernus Pharmaceuticals to Announce Second Quarter 2025 - GlobeNewswire
SUPN SEC FilingsSupernus Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
CNS Drug Leader Supernus Pharmaceuticals Sets Q2 2025 Earnings Call with CEO Presentation - Stock Titan
Supernus Pharmaceuticals Faces 3.2% Share Decline: Sector Challenges ImpactNews and Statistics - IndexBox
(SUPN) Investment Report - news.stocktradersdaily.com
Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today - Yahoo Finance
Is Supernus Pharmaceuticals Inc. stock a growth or value playQuick Profit Idea Stream - Newser
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Lowered by Teacher Retirement System of Texas - Defense World
Why Supernus Pharmaceuticals Inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser
How Supernus Pharmaceuticals Inc. stock performs during market volatilityStrong Buy Recommendations - Newser
What makes Supernus Pharmaceuticals Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):